(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4.10% £ 1.650
Live Chart Being Loaded With Signals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases...
Stats | |
---|---|
Volumen de hoy | 1.89M |
Volumen promedio | 16.31M |
Capitalización de mercado | 21.27M |
EPS | £0 ( 2024-04-25 ) |
Próxima fecha de ganancias | ( £0 ) 2024-06-28 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -1.650 |
ATR14 | £0.0240 (1.45%) |
Volumen Correlación
Hemogenyx Pharmaceuticals Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hemogenyx Pharmaceuticals Correlación - Moneda/Commodity
Hemogenyx Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | £0 |
Beneficio Bruto: | £-645 681 (0.00 %) |
EPS: | £-0.00600 |
FY | 2023 |
Ingresos: | £0 |
Beneficio Bruto: | £-645 681 (0.00 %) |
EPS: | £-0.00600 |
FY | 2022 |
Ingresos: | £0 |
Beneficio Bruto: | £-2.60M (0.00 %) |
EPS: | £-0.00440 |
FY | 2021 |
Ingresos: | £0.00 |
Beneficio Bruto: | £-321 230 (0.00 %) |
EPS: | £-0.0123 |
Financial Reports:
No articles found.
Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico